Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.

NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators

TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.

METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help

NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product

COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors

INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
CRMD Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 17, 2026
Report Source: 2026 1st Quarter Report
CorMedix Inc. Stock Analysis CRMD
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Read More CorMedix Inc (CRMD) Chart
Key Statistics of CorMedix Inc (CRMD)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$8.75Volume
1.27MP/E Ratio (TTM)
4.2452 Week Range
Market Cap
632.32MAvg. Volume
1.27MDividend Yield
-Financial Metrics & Statements of CorMedix Inc (CRMD)
FAQ's for CorMedix Inc (CRMD)
- According to Musaffa’s Shariah screening methodology, CorMedix Inc (CRMD) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CorMedix Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in CorMedix Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of CorMedix Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of CorMedix Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of CorMedix Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.